Mycobacterium tuberculosis (M. tb), the causative agent of TB, is a recalcitrant pathogen that
is rife around the world, latently infecting approximately a quarter of the worldwide …

Tuberculosis (TB) was announced as a global emergency in 1993. There was an alarming
counter attack of TB worldwide. However, when it was known that TB can be cured …

Tuberculosis (TB) is a serious public health problem worldwide. Its situation is worsened by
the presence of multidrug resistant (MDR) strains of Mycobacterium tuberculosis, the …

In this Review, we explore natural product antibiotics that do more than simply inhibit an
active site of an essential enzyme. We review these compounds to provide inspiration for the …

The approval of bedaquiline has placed energy metabolism in the limelight as an attractive
target space for tuberculosis antibiotic development. While bedaquiline inhibits the …

Non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths globally.
Treatment-related adverse effects and development of drug resistance limit the available …

Abstract Drug-resistant (DR)-TB is the major challenge confronting the global TB control
programme, necessitating treatment with second-line anti-TB drugs, often with limited …

The FDA granted expedited approval for Johnson and Johnson's Bedaquiline to treat
pulmonary multidrug resistant tuberculosis on 28 December 2012 which is more common in …

Tuberculosis is one of the deadliest infectious diseases existing in the world since ancient
times and still possesses serious threat across the globe. Each year the number of cases …

Tuberculosis (TB) is reported as one of the most prevailing life-threatening health problems,
affecting almost one third of the population globally. It is one of a major reason of death with …